User profiles for Luis Jodar
 | Luis JodarChief Medical Officer, Vaccines, Pfizer Verified email at pfizer.com Cited by 7554 |
[HTML][HTML] Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a …
Background Following the emergency use authorisation of the Pfizer–BioNTech mRNA
COVID-19 vaccine BNT162b2 (international non-proprietary name tozinameran) in Israel, the …
COVID-19 vaccine BNT162b2 (international non-proprietary name tozinameran) in Israel, the …
[HTML][HTML] Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study
…, S Gray, SR Valluri, K Pan, FJ Angulo, L Jodar… - The Lancet, 2021 - thelancet.com
Background Vaccine effectiveness studies have not differentiated the effect of the delta (B.1.617.2)
variant and potential waning immunity in observed reductions in effectiveness against …
variant and potential waning immunity in observed reductions in effectiveness against …
Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a …
Background The duration of protection against the omicron (B.1.1.529) variant for current
COVID-19 vaccines is not well characterised. Vaccine-specific estimates are especially needed…
COVID-19 vaccines is not well characterised. Vaccine-specific estimates are especially needed…
Severity of Omicron (B. 1.1. 529) and Delta (B. 1.617. 2) SARS-CoV-2 infection among hospitalised adults: A prospective cohort study in Bristol, United Kingdom
Background There is an urgent public health need to evaluate disease severity in adults
hospitalised with Delta and Omicron SARS-CoV-2 variant infections. However, limited data exist …
hospitalised with Delta and Omicron SARS-CoV-2 variant infections. However, limited data exist …
Development of vaccines against meningococcal disease
L Jódar, IM Feavers, D Salisbury, DM Granoff - The Lancet, 2002 - thelancet.com
Neisseria meningitidis is a major cause of bacterial meningitis and sepsis. Polysaccharide–protein
conjugate vaccines for prevention of group C disease have been licensed in Europe. …
conjugate vaccines for prevention of group C disease have been licensed in Europe. …
[HTML][HTML] Salmonella paratyphi A rates, Asia
Little is known about the causes of enteric fever in Asia. Most cases are believed to be caused
by Salmonella enterica serovar Typhi and the remainder by S. Paratyphi A. We compared …
by Salmonella enterica serovar Typhi and the remainder by S. Paratyphi A. We compared …
Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer–BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a …
…, K Pan, J Southern, DL Swerdlow, L Jodar… - The Lancet Infectious …, 2022 - thelancet.com
Background On Dec 20, 2020, Israel initiated a nationwide COVID-19 vaccination campaign
for people aged 16 years and older and exclusively used the Pfizer–BioNTech BNT162b2 …
for people aged 16 years and older and exclusively used the Pfizer–BioNTech BNT162b2 …
Effectiveness of a third dose of BNT162b2 mRNA COVID-19 vaccine in a large US health system: a retrospective cohort study
…, S Gray, SR Valluri, K Pan, L Jodar… - The Lancet Regional …, 2022 - thelancet.com
Background Globally, recommendations are expanding for third (booster) doses of
BNT162b2 (Pfizer–BioNTech). In the United States, as of November 19, 2021, boosters were …
BNT162b2 (Pfizer–BioNTech). In the United States, as of November 19, 2021, boosters were …
BNT162b2 vaccine effectiveness against SARS-CoV-2 omicron BA. 4 and BA. 5
Correspondence 1664 www. thelancet. com/infection Vol 22 December 2022 emergency
department encounters only in the first 3 months after a third dose of vaccine (table). At 6 …
department encounters only in the first 3 months after a third dose of vaccine (table). At 6 …
Effectiveness of 13-valent pneumococcal conjugate vaccine against hospitalization for community-acquired pneumonia in older US adults: a test-negative design
…, WA Mattingly, JA Ramirez, L Jodar - Clinical Infectious …, 2018 - academic.oup.com
Background Following universal recommendation for use of 13-valent pneumococcal conjugate
vaccine (PCV13) in US adults aged ≥65 years in September 2014, we conducted the …
vaccine (PCV13) in US adults aged ≥65 years in September 2014, we conducted the …
